Related Experiment Video
Updated: Feb 4, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge
Daiana Cosmina Temian1,2, Laura Ancuta Pop1, Alexandra Iulia Irimie3
1Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Abstract:
Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remains elusive to targeted therapies-the triple-negative breast cancer. This immunohistochemically defined subtype is resistant to both endocrine and targeted therapies, leading to its poor prognosis. A field that is of great promise in current cancer research is epigenetics. By studying the epigenetic mechanisms underlying tumorigenesis-DNA methylation, histone modifications, and noncoding RNAs-advances in cancer treatment, diagnosis, and prevention are possible. This review aims to synthesize the epigenetic discoveries that have been made related to the triple-negative breast cancer.
Insights
Triple-negative breast cancer (TNBC) lacks targeted therapies. Epigenetic research, including DNA methylation and noncoding RNAs, offers new avenues for TNBC treatment and diagnosis.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Breast cancer is a leading cause of cancer in women, with significant progress in targeted therapies.
- Triple-negative breast cancer (TNBC) is a challenging subtype resistant to current endocrine and targeted treatments, resulting in poorer prognoses.
- Epigenetics, encompassing DNA methylation, histone modifications, and noncoding RNAs, presents a promising frontier for understanding and combating cancer.
Purpose of the Study:
- To review and synthesize current epigenetic discoveries specifically related to triple-negative breast cancer.
- To highlight the potential of epigenetic mechanisms in advancing the diagnosis, treatment, and prevention of TNBC.
Main Methods:
- Literature review of epigenetic mechanisms in cancer research.
- Focus on studies investigating DNA methylation, histone modifications, and noncoding RNAs in TNBC.
- Synthesis of findings to identify key epigenetic alterations in TNBC.
Main Results:
- Epigenetic alterations, including aberrant DNA methylation patterns and dysregulated noncoding RNAs, are frequently observed in TNBC.
- These epigenetic changes play crucial roles in TNBC initiation, progression, and therapeutic resistance.
- Specific epigenetic targets are emerging as potential biomarkers and therapeutic strategies for TNBC.
Conclusions:
- Epigenetics offers a promising avenue for developing novel therapeutic strategies and diagnostic tools for triple-negative breast cancer.
- Further research into epigenetic mechanisms is essential to overcome treatment resistance and improve outcomes for TNBC patients.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Laminins are the Adhesive Proteins of Basal Lamina
In humans, the five forms of alpha chains are LAMA 1, LAMA 2, LAMA 3, LAMA 4, and LAMA 5. The four forms of beta chains are LAMB 1, LAMB 2, LAMB 3, and LAMB 4. The three forms of gamma...
Negative Regulator Molecules
Positive, Negative, and Zero Work

